Stem cell therapy for preventing neonatal diseases in the 21st century: Current understanding and challenges

Area of Science:

• Neonatal Medicine
• Regenerative Medicine
• Cellular Therapy

Background:

• Preterm newborn diseases, including bronchopulmonary dysplasia and necrotizing enterocolitis, cause significant infant mortality and morbidity.
• Current therapies offer limited benefits, necessitating novel treatment strategies.
• Stem cell therapy presents a promising avenue for neonatal diseases, with encouraging preclinical data.

Purpose of the Study:

• To review the potential of mesenchymal stromal cells (MSCs) in treating neonatal diseases.
• To highlight the promises and challenges associated with the clinical translation of MSC therapy.
• To identify key areas for future research in neonatal stem cell therapeutics.

Main Methods:

• Review of current literature on stem cell therapy for neonatal diseases, focusing on mesenchymal stromal cells.
• Analysis of preclinical findings and ongoing clinical trials.
• Discussion of mechanistic insights, therapeutic optimization, and translational challenges.

Main Results:

• Mesenchymal stromal cells demonstrate potential therapeutic effects through anti-inflammatory and pro-angiogenic mechanisms.
• Significant knowledge gaps exist regarding optimal therapy type (cellular vs. secretomes), timing, and patient selection.
• The interaction between stem cell therapy and standard care is largely unexplored.

Conclusions:

• Mesenchymal stromal cell therapy holds considerable promise for preventing and treating major neonatal diseases.
• Elucidating mechanisms, optimizing therapeutic parameters, and understanding interactions with standard care are critical for successful clinical translation.
• Further research is essential to harness the full potential of stem cell therapy for improving neonatal health outcomes.